Osteoarthritis

Why you shouldn’t be afraid to start running after middle age

Retrieved on: 
Friday, April 19, 2024
Knee, Atrophy, Pressure, MRI, Osteopenia, Exercise, Walking, Activity, Cell, Bone marrow, Chemical oxygen demand, Risk, Gamer, Research, Sarcopenia, Running, Rest, Joint, Volunteering, Life, Arthritis, Osteoporosis, Spine, Bed rest, Cartilage, Osteoarthritis, Skeleton, Dietary supplement

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.

Key Points: 
  • As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.
  • Hobbling around my orthopaedic hospital after my first marathon actually led me to do research on runners.
  • The high-resolution MRI scans found most of the 115 middle-aged participants had abnormalities in their knees before starting marathon training.
  • But while osteoarthritis is more common after middle age, it may actually be a lack of activity that leads to osteoarthritis.
  • Reduced muscle use, whether it is through inactivity or sarcopenia or both, also reduces the production of anti-inflammatory myokines from the muscles.
  • These chemicals are released when we exercise, and help reduce joint swelling and calm irritated joint linings.
  • This effect is pronounced in runners because running uses some of the largest muscles in the body – such as the glutes, quadriceps and hamstrings.

Where to begin

  • If you want to start running, the main message is to ease into it to reduce the risk of injury.
  • One of the best ways to ease into running in mid-life is the NHS Couch to 5K running programme.
  • It’s a free guide that will help you gradually work up towards running 5km in just nine weeks.
  • If you’ve experienced any of these problems, you’ll want to be careful when exercising to avoid further damage.


Alister Hart receives funding from 3 charities: The Rosetrees Trust, Arthroplasty for Arthritis and The Maurice Hatter Foundation.

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Anthraquinones, Skin cancer, Epidermolysis bullosa, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Joint, Protein, Life expectancy, Deformity, Blister, Interleukin-1 family, Mouth, European, Skin, Collagen, COMP, Infection, Safety, European Commission, Pain, Osteoarthritis, Marketing, Swelling, FGK, Medicine, Pharmaceutical industry

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
Wednesday, April 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA

Retrieved on: 
Monday, April 8, 2024
Arthralgia, Osteoarthritis, DVM, Mayra Andrade, Hip, Patient, Synovial joint, Pain management, ACVS, Limp, Quality of life, Trial of the century, Dog, JW Marriott Hotels, JW Marriott Indianapolis, Joint, Pain, CCRT, VOS, Animal, CCD, Poultry farming

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/
    Pain Management Forum Exhibit Details:
    Location: The JW Marriott in Indianapolis, Indiana
    Presentation Title: How do we Elevate Our Strategy for Managing Osteoarthritis in Pets?

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN NAPLES FLORIDA

Retrieved on: 
Wednesday, April 3, 2024
Arthralgia, Osteoarthritis, American College, Joint, Pet, Animal, Sports medicine

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN CHARLESTON, SOUTH CAROLINA

Retrieved on: 
Wednesday, April 3, 2024
Arthralgia, Osteoarthritis, American College, Joint, Pet, Animal, Sports medicine

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Retrieved on: 
Tuesday, April 2, 2024
Press club, B cell, Longevity, TELO, Chromosome, Research, DNA, MD, Skin, Osteoarthritis, Blood, Ageing, Pharmaceutical industry

BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024. Dr. Roizen serves as Telomir’s special advisor on age reversal.

Key Points: 
  • Dr. Roizen serves as Telomir’s special advisor on age reversal.
  • The search for treatments to combat the diseases of aging has increasingly become the focus of many medical professionals and, more recently, society in general.
  • “Our event at the National Press Club will provide us with an opportunity to share Telomir-1’s potential with the public on a national stage,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir Pharmaceuticals.
  • As Telomir continues to uncover new and promising data through our pre-clinical work, we remain committed to sharing our data publicly.

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Plural, Cell, Science, Coffee, Research, Elective surgery, 3D, OA, Carbon, MIW, Osteoarthritis, Education minister, Facial muscles, PLUR

Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation.

Key Points: 
  • Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation.
  • The Company is leveraging two decades of experience and know-how in cell manufacturing to drive the future of coffee science.
  • Pluri’s Chief Executive Officer & President Yaky Yanay will participate in a panel of discussions and Chief Business Development Officer of Pharma Efrat Kaduri will attend the event.
  • It demonstrated increased muscle strength in two clinical studies and is believed to induce systemic anti-inflammatory effect and to reduce post-operative oxidative stress.

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Retrieved on: 
Friday, March 29, 2024
Diagnosis, B cell, Regeneration, TELO, Disease, Research, Nonsteroidal anti-inflammatory drug, MD, Quality of life, Human, Osteoarthritis, FDA, Ageing

BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.

Key Points: 
  • The study will evaluate the efficacy of Telomir-1 for mitigating the progression of osteoarthritis based on symptomatic, radiographic, gross pathologic and histopathologic evaluations.
  • In addition, Telomir believes that this study could be used as part of its pre-clinicial program for eventually evaluating Telomir-1 in humans.
  • It is estimated that nearly 18 million canines in the United States are affected by osteoarthritis.
  • “Osteoarthritis is the most common ailment in canines yet there are currently no treatments that combat the disease.

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Longevity, Rheumatoid arthritis, Prevalence, Partnership, Patient, AAOS, Elbow, Polyethylene, American Academy, Acquisition, Motion, Quality of life, Injury, Integra, Shoulder, Metal, Partial, Key, Pain, Osteoarthritis, USD, Collection, Plumbing

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.